Nektar Therapeutics Statistics Share Statistics Nektar Therapeutics has 19.02M
shares outstanding. The number of shares has increased by -7.15%
in one year.
Shares Outstanding 19.02M Shares Change (YoY) -7.15% Shares Change (QoQ) -7.33% Owned by Institutions (%) 58.71% Shares Floating 17.59M Failed to Deliver (FTD) Shares 89 FTD / Avg. Volume 0.01%
Short Selling Information The latest short interest is 1.61M, so 8.45% of the outstanding
shares have been sold short.
Short Interest 1.61M Short % of Shares Out 8.45% Short % of Float 8.62% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -1.61 and the forward
PE ratio is -4.7.
Nektar Therapeutics's PEG ratio is
0.03.
PE Ratio -1.61 Forward PE -4.7 PS Ratio 1.94 Forward PS 27.4 PB Ratio 3.15 P/FCF Ratio -1.08 PEG Ratio 0.03
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Nektar Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 4.26,
with a Debt / Equity ratio of 1.69.
Current Ratio 4.26 Quick Ratio 4.26 Debt / Equity 1.69 Debt / EBITDA -1.18 Debt / FCF -0.58 Interest Coverage -3.74
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $1.61M Profits Per Employee $-1.95M Employee Count 61 Asset Turnover 0.32 Inventory Turnover n/a
Taxes Income Tax -239K Effective Tax Rate 0.2%
Stock Price Statistics The stock price has increased by 233.33% in the
last 52 weeks. The beta is 1.07, so Nektar Therapeutics's
price volatility has been higher than the market average.
Beta 1.07 52-Week Price Change 233.33% 50-Day Moving Average 34.18 200-Day Moving Average 18.47 Relative Strength Index (RSI) 72.27 Average Volume (20 Days) 1,325,223
Income Statement In the last 12 months, Nektar Therapeutics had revenue of 98.43M
and earned -118.96M
in profits. Earnings per share was -8.68.
Revenue 98.43M Gross Profit 67.74M Operating Income -105.2M Net Income -118.96M EBITDA -86.7M EBIT -91.09M Earnings Per Share (EPS) -8.68
Full Income Statement Balance Sheet The company has 44.25M in cash and 102.56M in
debt, giving a net cash position of -58.31M.
Cash & Cash Equivalents 44.25M Total Debt 102.56M Net Cash -58.31M Retained Earnings -3.6B Total Assets 207.53M Working Capital 115.17M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -175.71M
and capital expenditures -1.47M, giving a free cash flow of -177.18M.
Operating Cash Flow -175.71M Capital Expenditures -1.47M Free Cash Flow -177.18M FCF Per Share -12.92
Full Cash Flow Statement Margins Gross margin is 68.82%, with operating and profit margins of -106.88% and -120.86%.
Gross Margin 68.82% Operating Margin -106.88% Pretax Margin -121.1% Profit Margin -120.86% EBITDA Margin -88.08% EBIT Margin -106.88% FCF Margin -180.01%
Dividends & Yields NKTR does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for NKTR is $105,
which is 79.5% higher than the current price. The consensus rating is "Strong Buy".
Price Target $105 Price Target Difference 79.5% Analyst Consensus Strong Buy Analyst Count 6
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jun 9, 2025. It was a
backward
split with a ratio of 1:15.
Last Split Date Jun 9, 2025 Split Type backward Split Ratio 1:15
Scores Altman Z-Score -22.41 Piotroski F-Score 3
